FDA-Approved: Why You Should Add 22nd Century Group, Inc. (NASDAQ: XXII) to Tomorrow's Watchlist

Our Next Profile is 22nd Century Group, Inc. (NASDAQ: XXII)! It’s Time to Get 22nd Century Group, Inc. (NASDAQ: XXII) on Your Watchlist! 22nd Century Group, Inc. (NASDAQ: XXII) comes backed by several potential catalysts including: 1. Limited Float: Fewer than 9M shares in float, creating potential for significant movements if demand shifts! 2. High Growth Potential: With a market cap under $3M, 22nd Century Group, Inc. (NASDAQ: XXII) has a higher potential for growth! 3. Strong Technical Indicators: Currently in an oversold range based on RSI levels, signaling a potential trend reversal! 4. Recent Market Recognition: 22nd Century Group, Inc. (NASDAQ: XXII) just made an approximate 31% move over two trading sessions, reflecting momentum and the potential for continued shifts! 5. Unique Product Offering: The only company with FDA approval for a low-nic-o-tine cig-a-rette, the VLN®, containing 95% less nic-o-tine! 6. Harm Reduction Focus: A 26-year mission focused on reducing nic-o-tine consumption, positioning 22nd Century Group, Inc. (NASDAQ: XXII) as a pioneer in public health efforts! 7. FDA Approval: VLN® has received FDA authorization as a Modified Risk Tobacco Product (MRTP), providing a competitive edge and regulatory validation! 22nd Century Group, Inc. (NASDAQ: XXII) Needs to be on Your Radar! September 10, 2024 Dear Reader, Few sectors offer the potential for small, single-product companies to rapidly transition from modest market capitalizations to much larger ones, practically overnight. But the biotech sector is different. The ability to address major health challenges or discover cures for diseases often garners significant market attention, especially for companies showing potential for major advancements. 22nd Century Group, Inc. (NASDAQ: XXII) is one such biotech company that deserves close attention. The company is focused on nic-o-tine harm reduction through innovative biotechnology, positioning itself uniquely in both the to-bacco and plant biotechnology sectors by developing a product aimed at reducing nic-o-tine consumption. With a market cap under $3M and a float of fewer than 9M shares, 22nd Century Group stands out for its growth potential. Current technical indicators suggest the company may be in an oversold range, with RSI levels at: 9-Day: 30.38% 14-Day: 28.86% 20-Day: 30.27% These levels signal the possibility of a trend reversal. Recently, 22nd Century Group, Inc. (NASDAQ: XXII) saw an approximate 31% move in just two sessions, going from $.2557 on 9/6/2024 to $.3372 on 9/9/2024.  With shares trading as high as $.75 just a month ago on 8/13/2024, and opening around $.33 this morning, there's a strong case for keeping an eye on this stock. Keep reading to see why 22nd Century Group, Inc. (NASDAQ: XXII) should be on your watchlist tomorrow... 22nd Century Group, Inc. (NASDAQ: XXII) is a Biotechnology Company with a 26-year mission dedicated to nic-o-tine Harm Reduction through advanced plant science and genetic engineering. The company’s focus is on developing solutions that reduce nic-o-tine consumption, highlighted by their branded VLN® Low nic-o-tine cig-a-rette—the only low nic-o-tine cig-a-rette on the market.  Through innovative biotechnology, 22nd Century Group aims to address the global issue of nic-o-tine addiction and improve public health. Commitment to nic-o-tine Harm Reduction: Since its founding in 1998, 22nd Century Group has remained focused on creating to-bacco products that help smokers reduce their nic-o-tine intake.  In December 2021, the company received the first and only FDA Modified Risk to-bacco Product (MRTP) authorization for their VLN® cig-a-rette, which contains 95% less nic-o-tine than conventional cig-a-rettes.  This FDA authorization solidified 22nd Century Group’s role as a leader in developing solutions that reduce nic-o-tine consumption, making the VLN® cig-a-rette a healthier alternative for smokers. With their slogan, "VLN® - Helps You Smoke Less®," the company’s goal is clear: to offer smokers a practical way to reduce nic-o-tine consumption while addressing addiction. Advanced Biotechnology and Intellectual Property: 22nd Century Group’s success is rooted in their patented technology that allows them to control nic-o-tine biosynthesis in to-bacco plants.  Their Reduced nic-o-tine Content (RNC) to-bacco plants are the foundation of their VLN® cig-a-rettes, which are the only low-nic-o-tine cig-a-rettes available today. This technology provides the company with a unique competitive advantage in the to-bacco market. Modern Plant Breeding Technologies: Beyond nic-o-tine reduction, 22nd Century Group employs genetic engineering, gene-editing, and molecular breeding technologies to improve the traits of their to-bacco plants.  These proprietary plant varieties exhibit improved yields, select alkaloid levels, and other valuable features.  The company’s expertise extends beyond the to-bacco industry, positioning them to contribute to life sciences and consumer products. The company’s innovations in genetic engineering also extend to improving disease resistance and optimizing alkaloid content, further enhancing their impact on both the agricultural and health sectors. Expanding the VLN® Brand: Building on the success of VLN®, 22nd Century Group is expanding its low-nic-o-tine product line by introducing new flanker brands such as Ranger VLN® and Pinnacle VLN®.  These products aim to strengthen the company’s leadership in the nic-o-tine harm reduction space by offering more low-nic-o-tine options.  The goal is to establish a new category of to-bacco products, much like how decaf coffee, light beer, and diet soda provide healthier alternatives. Strategic Growth and Distribution: Currently, VLN® products are available in over 5,100 retail stores across 26 U.S. states, including major markets such as Texas, California, and Florida. With more than 274,000 to-bacco retailers in the U.S., 22nd Century Group could see significant growth potential.  Their NASCO division supports this expansion by providing private-label contract manufacturing services, which helps fund core operations while scaling manufacturing capabilities. Path to Pro-fit-ability: As 22nd Century Group grows, they are targeting breakeven profitability by Q1 2025.  This is being driven by increasing VLN® sales, optimizing product mixes for better gross margin profitability, and expanding contract manufacturing operations. Efforts to reduce operating expenses and restructure debt further position the company for sustained profitability. Research and Development: Advancing Plant Science: Research and development (R&D) is essential to 22nd Century Group’s strategy.  In collaboration with North Carolina State University (NCSU), they continue to enhance their low-nic-o-tine to-bacco strains.  Their R&D efforts include improving disease resistance, developing future VLN® blends, and filing new patents to protect their innovations. Their international patent strategy ensures 22nd Century maintains its leadership in nic-o-tine harm reduction while continuing to create value for shareholders. Contract Manufacturing: Boosting Production and Revenue: In addition to their proprietary products, 22nd Century Group offers private-label manufacturing services through their NASCO division.  This allows the company to offer high-quality production solutions to other to-bacco companies while maximizing their manufacturing output.  Operating at full capacity supports both VLN® production and revenue growth. Key Developments at 22nd Century Group, Inc. (NASDAQ: XXII) NCSU Partnership Secured Through 2025: Recently, 22nd Century Group finalized a significant agreement with North Carolina State University (NCSU) to fund intellectual property, licensing, and sponsored research obligations through 2025, valued at over $1.2M. This partnership ensures the company will continue to enhance its reduced nic-o-tine content (RNC) to-bacco capabilities. CEO Larry Firestone commented: “This agreement strengthens our relationship with NCSU and supports our continued success in advancing nic-o-tine harm reduction.” New CMO Contract to Boost Production by 20%: In April 2024, 22nd Century Group signed a new contract manufacturing (CMO) agreement, increasing production volumes by over 20% at their manufacturing facility. The contract is expected to generate revenue starting in Q2 2024, supporting their VLN® franchise. Larry Firestone commented: “This new contract is a key step in scaling our contract manufacturing business while continuing to build our VLN® franchise.” The agreement aligns with the company’s goal of breakeven operations by Q1 2025. The Road Ahead: As 22nd Century Group continues to lead the nic-o-tine harm reduction movement, their innovative use of biotechnology and genetic engineering positions them for long-term success. Their strategy includes expanding VLN® distribution, building consumer awareness, and continuing to push the boundaries of plant science.  With a strong R&D pipeline and a clear path to profitability, Century Group, Inc. (NASDAQ: XXII) is positioning itself to reshape the to-bacco industry and improve public health. 7 reasons to get 22nd Century Group, Inc. (NASDAQ: XXII) on your watchlist before tomorrow! 1. Limited Float: The company has fewer than 9M shares in its float, which could lead to significant price movements as demand increases. 2. High Growth Potential: With a market cap under $3M and a nano-cap status, XXII has considerable room for potential growth. 3. Strong Technical Indicators: Current technical analysis suggests that the stock is in an oversold range, with RSI levels signaling the potential for a trend reversal. 4. Recent Market Recognition: XXII saw a 31% increase over just two trading sessions, indicating recent momentum and the possibility of continued shifts. 5. Unique Product Offering: 22nd Century Group is the only company with an FDA-approved low-nic-o-tine cig-a-rette, the VLN®, which contains 95% less nic-o-tine than conventional cig-a-rettes. 6. Nic-o-tine Harm Reduction Focus: The company's 26-year mission is centered on reducing nic-o-tine consumption—an area gaining more attention in public health, making it a pioneer in this space. 7. FDA Approval: The FDA authorization for their VLN® cig-a-rette as a Modified Risk to-bacco Product (MRTP) provides a competitive advantage and validation from a key regulatory body. With fewer than 9M shares in its float, 22nd Century Group, Inc. (NASDAQ: XXII) presents the potential for significant movements if demand shifts. The company's nano-cap status and market cap under $3M highlight its higher potential for growth.. Recent technical analysis points to a potential trend reversal, supported by its approximate 31% move over two sessions. As the only company with FDA approval for a low-nic-o-tine cig-a-rette, the VLN®, 22nd Century Group, Inc. (NASDAQ: XXII) continues to pioneer efforts in nic-o-tine harm reduction—a focus they've maintained for 26 years. With products already in 5,100 U.S. retail stores and plans to expand further, alongside cutting-edge biotechnology innovations and a strategy targeting breakeven pro-fit-ability by Q1 2025,22nd Century Group, Inc. (NASDAQ: XXII) is poised to continue making a significant impact in both the to-bacco and plant biotechnology sectors. Get 22nd Century Group, Inc. (NASDAQ: XXII) on your watchlist for tomorrow. Pull up (XXII) and start your research. I’ll check back in with you tomorrow morning. Have a good night. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends (stocknewstrends . com) is owned by TD Media LLC, a limited liability company. Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. StockNewsTrends full disclosure is to be read and fully understood before using StockNewsTrends website, or joining StockNewsTrends' email or text list. By viewing StockNewsTrends's website and/or reading StockNewsTrends email or text newsletter you are agreeing to StockNewsTrends's full disclosure which can be read at https://stocknewstrends.com/disclosure/ Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockNewsTrends (stocknewstrends . com) is owned by TD Media LLC, a limited liability company. Pursuant to an agreement between TD Media LLC and Axiom Financial Inc., TD Media LLC has been hired for a period beginning on 09/10/2024 and ending on 09/11/2024 to publicly disseminate information about (XXII:US) via digital communications. We have been paid an additional fifty thousand USD. To date, we have been paid five hundred sixty-four thousand USD. We own zero shares of (XXII:US). Please see important disclosure information here: https://lifewatermedia.com/xxii-disclosure-7612/

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice